MedTrace Logo

Acute Effects of Radiofrequency Diathermy in Postpartum Women With Diastasis Abdominis

NCT07419399 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-02-19

No results posted yet for this study

Summary

This clinical trial aims to compare the immediate tissue response in postpartum women with and without rectus abdominis diastasis (RAD) after undergoing radiofrequency diathermy (RFD) treatment. The main question it seeks to answer is: Do postpartum women with and without RAD exhibit different acute tissue responses in terms of pressure pain threshold, superficial thermal sensitivity, and tissue elasticity? To determine whether there are differences in these acute tissue responses between the groups, researchers will compare RFD with a sham RFD intervention in postpartum women with and without RAD.

Participants will receive one session of either RFD or a sham RFD intervention and will complete three assessments: one at baseline and two after the intervention, one immediately afterwards and one 20 minutes afterwards.

Conditions

  • Postpartum
  • Rectus Muscle Diastasis

Interventions

OTHER

Radiofrequency diathermy (RFD)

RFD for 20 minutes, with 10 minutes applied using the capacitive method and 10 minutes using the resistive method.

OTHER

Radiofrequency diathermy (RFD)

RFD for 20 minutes, with 10 minutes applied using the capacitive method and 10 minutes using the resistive method

OTHER

Sham radiofrequency diathermy ( sham RFD)

20 minutes of application of the RFD device without energy emission. 10 minutes using the capacitative electrode, and 10 minutes using the resistive electrode.

OTHER

Sham radiofrequency diathermy ( sham RFD)

20 minutes of application of the RFD device without energy emission.10 minutes using the capacitative electrode, and 10 minutes using the resistive electrode.

Sponsors & Collaborators

  • University of Valencia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2029-03-30
Completion
2029-03-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07419399 on ClinicalTrials.gov